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The coronary stent has been investigated as an 
adjunct to percutaneous transluminal coronary 
angioplasty to obviate the problems of early occlu- 
sion and late restenosfs. From March 1986 to 
March lSSO,265 patients (308 lesions) were im- 
planted with the coronary Wallstent@ in 6 Europe- 
an centers. For this study, the patients were ana- 
lyzed according to date of implantation (group 1, 
March 1986 to January 1988; group 2, February 
1986 to March 1990) and vessel type (native 
arteries versus bypass grafts). Quantitative angio- 
graphic follow-up was performed in 82% of the 
study patients. The early in-hospital occlusion rate 
in the overall group was 15%. Group 1 patients 
had a 20% rate in contrast to 12% rate in group 2 
(p = not significant [NS]). The early occlusion rate 
in native vessels and bypass grafts was 19 and 
8%, respectively (p = 0.019). Restenosis was de- 
termined by 2 criteria (criterion 1, 20.72 mm loss 
in minimal krminal diameter from poststent to fol- 
low-up; criterion 2, ~50% diameter stenosis at 
follow-up) within the stent and in the segments im- 
mediately proximal and distal to the stent. The re- 
steno& rate with criterion 1 was 43% in the over- 
all group of patients, 35% in group 1 versus 49% 
in group 2 (p = NS), and 34% in native vessels ver- 
sus 54% in bypass grafts (p = 0.016). The second 
criterion was met by 27% of patients in the over- 
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all group, 21% in group 1 versus 32% in group 2 
(p = NS), and 18% in native vessel versus 39% in 
bypass grafts (p = 0.005). The overall mortality 
during the study period was 6.6% in natlve arter- 
ies and 9% in bypass grafts (6 and 7.9% at 1 
year, respectively). The actuarial event-free sur- 
vival (freedom from death, myocardial infarctfon, 
bypass surgery or angloplasty) for native artery 
patients was 46% at 40 months and for bypass 
graft patients 37% at 20 months. 
It is concluded that early in-hospftal occlusions 
remain a major problem with thls device despfte 
improvement in the later experience. Although pa- 
tients with bypass grafts had a significantly lower 
early occlusion rate than those with implantation 
of native arteries, a significantly hfgher rate of 
late restenosfs limited the early benefits of stent- 
ing. The indications for stenting remain unknown 
and require results of randomized clinical studies. 
(Am J Cardiol lSS2;69:476481) 
I n 1986, the first coronary WallstentTM implantation ushered in a new era in interventional cardiology with the purpose of circumventing the 2 major limi- 
tations of coronary angioplasty, early acute occlusion 
and late restenosis.’ As with all new procedures, opera- 
tors of the device had to struggle with their own learn- 
ing curves at the same time that anticoagulation reg- 
imens and clinical indications and contraindications 
evolved from their clinical experience. In May 1988, the 
5 European centers testing this device agreed to set up a 
core laboratory for quantitative angiographic analysis in 
Rotterdam to assess the results objectively. In a previ- 
ous publication from our group, the late angiographic 
and clinical follow-up of the initial 105 patients was re- 
ported.2 These stent implantations were predominantly 
performed in native coronary vessels. In the period from 
February 1988 until March 1990, an additional 160 pa- 
tients underwent stent implantation in the coronary 
circulation. This second group was characterized by a 
predominance of bypass vessels and a different set of 
indications. In this report, we compared the late quanti- 
tative angiographic and clinical follow-up of this second 
group of patients with the initial group, and assessed 
bypass grafts versus native vessels. In particular, we 
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TABLE I Stent Implantations According to Date of Implantation 
Group 1 Group 2 
(March 1986- (February 1988- 
January 1988) March 1990) 
Vessels 107 175 
StenWnarrowlngs 1171114 2661194 
Site of narrowings 
Bypass conduits 29 (18%) 116 (60%) 
Native vessels 94 (82%) 78 (40%) 
LAD 62 (54%) 29 (15%) 
LC 8 (7%) 10 (5%) 
Right 24 (21%) 39 (20%) 
LAD = left anterior descending artery; LC = left circumflex artery. 
were interested in determining whether the changing 
patterns of patient selection and management based on 
the initial experience resulted in improved rates of early 
occlusion and late restenosis and whether the results of 
stents implanted in bypass grafts differed from native 
vessels. 
METHODS 
Study paienb: Two hundred sixty-five patients 
(308 narrowings) were enrolled after obtaining in- 
formed consent between March 1986 and March 1990 
at the participating centers. The study protocol was ap 
proved by the individual hospital ethics committees. The 
mean age of the population was 58 f 11 years and 84% 
were men. The study patients were grouped according 
to the date of implantation (March 1986 to January 
1988, February 1988 to March 1990, groups 1 and 2, 
respectively) and the vessel type (native vessel versus 
bypass graft) (Table I). The first period of stent implan- 
tations, until January 1988, has previously been report- 
ed.2 Almost 90% of the first group underwent implanta- 
tion at either Lausanne (n = 56) or Toulouse (n = 32). 
However, in the second period, about 80% of the pa- 
tients underwent implantation in Rotterdam (n = 80) 
and in Lausanne (n = 43). In Group 1, 117 stems were 
implanted in 114 narrowings, of which 82% were in na- 
tive vessels (in particular the left anterior descending 
artery). In group 2, 266 stents were implanted in 194 
narrowings, predominantly in bypass grafts. In this 
group, the right coronary artery was the most common 
vessel implanted in the native circulation. Two patients 
had stems placed in both a bypass graft and a native 
vessel. The indications for stenting also differed between 
the 2 vessel types (Figure 1). Native vessels were pri- 
marily stented to prevent a second restenosis or as 
a bail-out procedure for angioplasties complicated by 
abrupt closure or large dissections that interrupted an- 
terograde flow and were associated with clinical and 
electrocardiographic s gns of ischemia. However, in by- 
pass grafts, the principle indication was for primary le- 
sions that had not been previously treated with angio- 
plasty. 
In this trial, the endovascular prosthesis, Wallstent@, 
was provided by Schneider Europe, Zurich. The method 
of implantation and description of this stent has previ- 
ously been reported.1-5 Unconstrained stent diameter 
ranged from 2.5 to 6 mm and was selected to be 0.50 
mm larger than the stented vessel. In an effort to allevi- 
ate the problem of acute thrombosis, the stent design 
was changed in April 1989 with the introduction of a 
polymer-coated stent (Biogold@) for some stent sizes. By 
August 1989, all manufactured stents contained this 
particular polymer coating. 
The anticoagulation for the first period of implanta- 
tion has previously been described.2 Based on this initial 
clinical experience, a uniform anticoagulation schedule 
was followed at the centers. Therapy with acetylsalicylic 
acid, 1 g orally, was begun 1 day before the procedure. 
At the beginning of the procedure, patients received 
heparin, 10,000 IU intravenously, and in some cases, 
dextran infusions (500 mg/4 hours) were also given. 
Heparin (10,000 IU) and urokinase (100,000 U) were 
administered by intracoronary infusion during the pro- 
cedure. After the procedure, the heparin infusion was 
adjusted according to the activated partial thromboplas- 
tin time (desired range 80 to 120 seconds) in addition to 
initiating oral vitamin K antagonist herapy. Heparin 
was discontinued after the therapeutic oral anticoagula- 
tion level was stabilized (international normalized ratio 
>2.3). Acetylsalicylic acid (100 mg/day), dipyridamole 
(300 to 450 mg/day), and in some patients ulfinpyra- 
zone (400 mg/day) were also administered. 
Quantitative camnary arteriography and restenosis 
criteria: All cineangiograms were analyzed at the core 
laboratory in Rotterdam using the computer-assisted 
cardiovascular angiography analysis system which has 
previously been discussed in detai1.6%7 The minimal lu- 
minal diameter and percent diameter stenosis were de- 
termined before and after angioplasty, immediately af- 
ter stent implantation and at long-term follow-up in all 
patients using the average of multiple matched views 
with orthogonal projections wherever possible. The min- 
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imal luminal diameter (and the diameter stenosis using 
the reference diameter of the segment) of each segment 
immediately proximal and distal to the stent was also 
measured. 
Two different sets of criteria were applied to deter- 
mine the restenosis rate. We have found a change in 
minimal luminal diameter of 10.72 mm (criterion 1) to 
be a reliable indicator of angiographic progression of 
vessel narrowing and by no means implies functional or 
clinical significance.3~4~8 This value takes into account 
the limitations of coronary angiographic measurements 
and represents 2 times the long-term variability (i.e., the 
95% confidence intervals) for repeat measurements of a 
coronary obstruction using our system. Criterion 2 for 
restenosis was an increase of the diameter stenosis from 
<50% after stent implantation to 250% at follow-up. 
This criterion was selected since common clinical prac- 
tice continues to assess lesion severity by a percent ste- 
nosis. The 2 criteria were assessed within and in the 
segment immediately adjacent (proximal and distal) to 
the stent. 
In this study, late (i.e., documented after the initial 
discharge from hosuital) occlusion (n = 10 patients. 16 
but a late deterioration to 1.99 f 0.07 (p <O.OOOl ver- 
sus the poststent result) if early occlusions are excluded 
and 1.59 f 0.09 with the inclusion of the early oc- 
clusions (p <O.OOOl). Similarly, the minimal luminal 
diameter increased significantly in bypass narrowings 
from 1.39 f 0.06 to 2.81 f 0.06 after stenting with a 
late reduction to 2.21 f 0.11 and 2.03 f 0.12 with the 
exclusion and inclusion of early occlusions, respectively 
(p <O.OOOl). Diameter stenosis was significantly re- 
I 
TABLE II Angiographic Follow-Up 
Implantations (lesions/patients) 
Early occlusions 
Late follow-up 
Total 
No angiographic follow-up 
Death 
Early bypass surgery 
Refusal 
Technical 
Time to angiographicfollow-up 
Excluding early occlusions 
Including early occlusions 
308/265 
41140 
2141176 
2551216 (82%) 
53149 (18%) 
10 (4%) 
11 (4%) 
25 (9%) 
3 (1%) 
6.6 f 4.8 
5.7 2 5.0 
1esions)was regard&l as restenosis. -This contrasts with 
our earlier report in which we calculated a total occlu- 
sion rate that was then separated into early (in hospital) 
and late occlusions.2 In that report, the early and late 
occlusions were analyzed separately from the restenotic 
lesions. The current change was initiated to be consis- 
tent with our reports of late follow-up of angioplasty.4,9 
Statistical me- The data obtained by quantita- 
tive angiographic analysis are given as mean f standard 
error of the mean. The means for each angiographic 
variable before angioplasty, after stent and at follow-up *--.. BYPASSES 
were compared by analysis of variance. If significant 0.5 - - NATIVES 
differences were found, 2-tailed t tests were applied to 
pairs of data. The occlusion and restenosis rates were 
compared using a chi-square test. A statistical probabil- 
ity <0.05 was considered significant. 
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The late clinical follow-up was determined accord- 
ing to a life-table format using the Kaplan-Meier meth- I - 
od.i” The following events were considered clinical end 80- 
points: death, myocardial infarction, bypass surgery or 
nonsurgical revascularization (angioplasty or atherec- 50. 
tomy). The life table was constructed according to the 40- 
initial clinical event. 
30- 
RESULTS zo- 
The angiographic follow-up for the entire study pop 20 *-.*.. BYPASSES 
ulation was 82% (Table II). This includes patients with 10 
t 
- NATIVES 
documented early occlusions during hospital admission 
(n = 40) in addition to patients who had late (after the 
0’ 
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initial hospital discharge) angiography. The reasons ( - EARLY OCCL.) (+ EARLY OCCL.) 
why follow-up angiography could not be performed are 
listed in Table II. The time to angiographic follow-up FtGuRE *. ‘*lninmd w aameter(MLD)ofnathfe 
was 6.6 f 4.8 months if early occlusions are excluded -~bP-~-(pRE)~,* 
and 5.7 f 5.0 months with the early occlusions. 
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The angiographic data for individual lesions in by- arly w occwom(occL.).Ds=-stenods. 
pass grafts and native vessels are presented in Figures 2 b-r m - v (m) of netlve vessels d
and 3. In native vessels, there was a mean increase in bP-qrtb-Pmd-,--mih&ml1Eolkw- 
minimal luminal diameter (mm) from 1.17 f 0.04 to 
up.MeanvaluesdEdoW~~baen~wlth8nd 
2.53 f 0.04 immediately after stenting (p <O.OOOl), 
without w m d m w irrhosplw m 
MU)=- ~&mneter, 
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duced immediately after stenting in bypass grafts from 
60 f 1 to 23 f l%, but increased at late follow-up to 43 
f 3 and 38 f 3% with and without the early occlusions, 
respectively (p <O.OOOl versus the poststent result). 
Similar changes were observed in native vessels, 
In the overall group, the incidence of early in-hospi- 
tal occlusion was 15% in patients and 13% in lesion. In 
bypass grafts, early occlusions were documented in 7% 
of lesions (8% of patients) versus 18% of lesions (19% of 
patients) in native vessels (in lesions, p = 0.005; in pa- 
tients, p = 0.016). Three of these native vessel occlu- 
sions occurred during the procedure and could not be 
recanalized. The remaining occlusions presented clini- 
cally as acute ischemic syndromes after a successful 
stenting procedure. Early occlusions were less frequent 
in group 2 (12%) than in group 1 (20%) patients but not 
statistically significant. Restenosis in the overall group 
according to criteria 1 and 2 was 42% and 27%, respec- 
tively (Table III). Restenosis according to either defini- 
tion was significantly higher in bypass grafts (criterion 
1, 54%; criterion 2, 39%) than in native vessels (34 and 
18%, respectively) (criterion 1, p = 0.016; criterion 2, 
p = 0.001). Although the restenosis rates by either cri- 
terion were higher in group 2 than group 1, these differ- 
ences were not statistically significant. 
The overall mortality during the study period was 
9% (n = 9) for bypass grafts and 6.6% (n = 11) for na- 
tive vessels (8 and 6% at 1 year, respectively). The l- 
year mortality rate in group 1 and 2 patients was 7.6 
and 7.5%, respectively. In patients who underwent by- 
pass surgery, 4 deaths occurred during the initial hospi- 
talization (2 intracerebral hematomas related to the 
anticoagulation and 2 myocardial infarctions due to 
stent occlusion). Two of the 5 late deaths were sudden 
(at 2 and 18 months), 2 were unrelated to the stent 
(chronic heart failure, renal failure), and the other 
death occurred after bypass urgery. In the stented na- 
tive vessel group, 7 of the 11 deaths occurred in the 
hospital. These were due to myocardial infarctions re- 
sulting from stent occlusion, with the exception of 1 pa- 
tient with intracerebral bleeding and 1 in cardiogenic 
shock who underwent stent implantation 24 hours after 
a myocardial infarction. Two of the 4 late deaths were 
sudden (at 1.5 and 19 months), 1 was noncardiac 
(pneumonia) and the other occurred after bypass sur- 
gery. The actuarial event-free survival (freedom from 
death, myocardial infarction, bypass surgery or angio- 
plasty) for native artery patients was 46% at 40 months 
and for bypass graft patients 37% at 20 months (Figure 
4). 
DISCUSSION 
The coronary Wallstent was initially introduced as 
an endovascular device to prevent the late restenosis 
process that limits percutaneous transluminal coronary 
angioplasty. The indications for and management ofpa- 
tients implanted with this particular prosthesis have 
evolved as experience and knowledge have increased. In 
this study, an attempt has been made to separate 2 im- 
portant factors in the late outcome of patients with stent 
implantations. The first division, according to date 
of implantation, provides the clearest picture of the 
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changes in stem applications based on the early experi- These occlusions, often with disastrous clinical sequelae, 
ence. Investigators originally believed that the stent convinced most of the investigators that native vessels in 
could be safely implanted in native vessels and that the general and particularly in the left anterior descending 
benefit of stents would be most apparent in lesions that artery (due to the large territory at risk) should only be 
had already restenosed on at least 1 occasion. However, implanted in bailout situations. Group 2 mainly consist- 
a high in-hospital occlusion rate was noted, particularly ed of patients with bypass grafts who underwent stent 
in patients with unstable syndromes, evolving myocardi- implantation for primary lesions and those in whom na- 
al infarction or angiographic evidence of thrombus. tive vessels were implanted as part of a bailout strategy 
TABLE III Late Angiographic Follow-Up: Restenosis Within and Immediately Adjacent to the Stent 
Total Group 1 Group 2 Native Vessels 
Narrowings/patients 
0.72 mm criterion 
Within stent 
Adjacent to stent 
Total 
50% drameter stenosis criterion 
Within stent 
Adjacent to stent 
Total 
214/176 85175 129/101 111/104 
75161 25121 50/40 35130 
14114 515 919 515 
89175 30/26 59749 40135 
(42%/43%) (37%/35%) (46%/49%) (36%/34%) 
51142 17115 34127 21/18 30124 
6/6 l/l 515 l/l 515 
57148 18/16 39132 22/19 35129 
(27%/27%) (22%/21%) (30%/32%) (20%/ 18%) (34%/39%) 
Bypass Grafts 
103174 
40131 
9/g 
49140 
(48%154%) 
1 .oo 
0.90 
------_------__ 
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after complicated angioplasty. Bypass grafts, in par- 
ticular, were selected for stent implantations owing to 
an extremely high rate of restenosis after angioplasty 
alone, and the larger diameter of these grafts seemed 
less likely to thrombose than smaller caliber native arte- 
rial vessels. l i-l4 Bypass lesions, which composed most of 
the lesions implanted in group 2, were generally more 
complex than group 1 lesions owing to the advanced age 
and diffuse nature of the disease in the bypass grafts. 
As a result, more stents per lesion (1.4 versus 1.1 in 
native vessels) were required to cover these lesions. 
Therefore, the significantly lower rate of in-hospital oc- 
clusion in patients with bypass grafts versus patients 
with native vessels (8 versus 19%) and the trend in 
group 2 versus group 1 (12 versus 20%) are indicative of 
several possible factors including improvements in anti- 
coagulation regimens, operator experience or larger cal- 
iber vessels despite more complex case selection. Higher 
restenosis rates by both criteria were demonstrated in
bypass grafts and in group 2 patients. There are 2 possi- 
ble explanations for this increase. First, bypass grafts, 
which are overrepresented in group 2, are known to 
have higher restenosis rates than native vessels.“-I3 Sec- 
ond, higher restenosis rates may be the “price” for low- 
er occlusion rates. Organization of thrombus at the site 
of intimal damage may be an important cause of late 
restenosis after stenting. Although it is often difficult to 
histologically differentiate thrombus organization from 
intimal hyperplasia, we have observed an extremely dis- 
organized pattern of intimal thickening in the stented 
segments of several bypass grafts that have been surgi- 
cally retrieved or obtained by atherectomy 1 to 5 
months after stent implantation.15 By diminishing the 
formation of early occlusive thrombus with more effec- 
tive anticoagulation, the residual nonoccluding throm- 
bus could form the substrate for late restenosis. Al- 
though the second group had a higher proportion of 
bailout cases, a previous tudy from our group did not 
identify increased relative risk for restenosis from bail- 
out cases compared with primary or restenosed le- 
sions.16 
The high incidence of late adverse clinical events in 
patients with stems is a cause for concern. A mortality 
rate of 9% in bypass grafts and 6.6% in native vessels is 
higher than in reported angioplasty studies.17-lg How- 
ever, it must be stressed that a large number of stents in 
native vessels were implanted for abrupt closure after 
angioplasty, which dramatically increases the risk of the 
procedure.20 Actuarial event-free survival was 37% at 
20 months in patients who had had bypass urgery and 
46% at 40 months in native vessels. In the bypass group, 
about 30% of the adverse vents were unrelated to the 
stented lesion and were due to worsening of a different 
lesion or to development of new lesions. In the native 
vessel group, 12% of the adverse vents were unrelated 
to the stented lesion. In addition, 9 of the 30 bypass 
operations in patients with stented native vessels were 
performed as part of a protocol for patients tented for 
the bailout indication.20 Although there are no compa- 
rable series of patients with stented native vessels in the 
literature because of the unique set of indications in our 
study, 3 recent reports have been published on late clini- 
cal follow-up after angioplasty in bypass grafts. The 
Thoraxcenter eported that only 41% of patients were 
alive and event-free (myocardial infarction, repeat by- 
pass surgery, repeat angioplasty) at a median follow-up 
of 2.1 years. 21 A review of the overall Dutch experience 
also showed limited late beneficial results with a 2- and 
5-year event-free survival of 52 and 26%, respectively, 
in 454 patients who underwent bypass urgery.22 Webb 
et al1 l described a 71% freedom from death, infarction 
and surgery at 5 years in bypass patients who under- 
went angioplasty at their institution, but did not include 
the 27% incidence of second angioplasty procedures also 
required in their patient group. However, our study was 
not a randomized trial designed to compare stenting 
with angioplasty, but rather an observational study with 
a first-generation coronary stent. Nevertheless, all of 
these late follow-up studies of nonoperative coronary re- 
vascularization clearly show that these are palliative 
procedures and not long-term solutions to the underly- 
ing problems of progression of underlying coronary dis- 
ease and iatrogenically induced restenosis. 
Several important points emerge from this study. Al- 
though in-hospital occlusion rates improved in the later 
experience, thrombosis of the Wallstent continues to 
limit its use. Restenosis rates with the 50% diameter 
stenosis criterion do not seem to be significantly im- 
proved when compared with historical results after an- 
gioplasty, although definitive statements must await 
randomized trials. Bypass grafts, in particular, had a 
high incidence of late restenosis, although early occlu- 
sion occurred less significantly than in native vessels. 
There is insufficient evidence at this time to implant a 
coronary stent outside of a randomized trial with the 
following exceptions: (1) bailout for abrupt occlusion; 
(2) suboptimal (inadequate dilatation) results after an- 
gioplasty; and (3) bypass grafts at high risk (e.g., friable 
lesions) for distal embolization with angioplasty that 
may benefit from the scaffolding property of the Wall- 
stent. 
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APPENDIX 
Participating Centers and Collaborators: Catheter- 
ization Laboratory for Clinical and Experimental Im- 
age Processing, Thoraxcenter, Rotterdam, the Nether- 
lands: B.H. Strauss, MD, K.J. Beatt, MB, BS, M. v.d. 
Brand, MD, P.J. de Feyter, MD, H. Suryapranata, 
MD, I.K. de Schecrder, MD, J.R.T.C. Roelandt, MD, 
P.W. Serruys, MD; Department of Cardioldgy, Hopital 
Cardiologique, Lille, France: M.E. Bertrand; Depart- 
ment of Invasive Cardiology, The Royal Brompton and 
National Heart Institute, London, United Kingdom: 
A.F. Rickards, MD, U. Sigwart, MD; Department of 
Clinical and Experimental Cardiology, CHRU Ran- 
geuil, Toulouse, France: J.P. Bounhoure, MD, A. Cour- 
tault, MD, F. Joffre, MD, J. Puel, MD, H. Rousseau, 
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MD; Division of Cardiology, Department of Medicine, 
CHUV, Lausanne, Switzerland: J.-J. Goy, MD, J-C 
Stauffer, MD, U. Kaufmann, MD, L. Kappenberger, 
MD, P. Urban, MD; Cardiology Center, University 
Hospital, Geneva, Switzerland: B. Meier, P. Urban. 
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